New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder

NLS Pharmaceutics Ltd NLSP has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience.
Narcolepsy is a chronic sleep disorder caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.
The new data confirm mazindol's Orexin-2 receptor (OX2R) agonist activity.
In the pre-clinical study conducted by the Department of Biomedical Sciences at the University of Lausanne and sponsored by NLS, mice genetically modified not to express OX2R (Knock-Out mice) and Wild-Type mice (normal mice) were investigated for psychostimulant effects when mazindol was administered.
The study demonstrated that Knock Out mice were 70% less sensitive to mazindol than normal mice, confirming mazindol's potent activity as an OX2R agonist.
Price Action: NLSP shares are up 0.58% at $3.39 on the last check Tuesday.